Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery

被引：4

作者：

Meng, Fanda ^{[1
]}

Qiao, Xinyu ^{[1
]}

Xin, Chenglong ^{[2
]}

Ju, Xiaoli ^{[3
]}

He, Meilin ^{[3
]}

机构：

[1] Shandong First Med Univ & Shandong Acad Med Sci, Coll Clin & Basic Med Sci, Jinan, Peoples R China

[2] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China

[3] Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai, Shandong, Peoples R China

来源：

JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2024年 / 27卷

关键词：

polymeric; microneedles; drug delivery systems; transdermal; long-acting drug release; SILK FIBROIN MICRONEEDLES; SUSTAINED-RELEASE; DISSOLVING MICRONEEDLES; INTRADERMAL DELIVERY; CANCER-IMMUNOTHERAPY; ACID MICRONEEDLES; DERMAL DELIVERY; HYALURONIC-ACID; ARRAYS; PATCH;

D O I：

10.3389/jpps.2024.12434

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Microneedle (MN)-assisted drug delivery technology has gained increasing attention over the past two decades. Its advantages of self-management and being minimally invasive could allow this technology to be an alternative to hypodermic needles. MNs can penetrate the stratum corneum and deliver active ingredients to the body through the dermal tissue in a controlled and sustained release. Long-acting polymeric MNs can reduce administration frequency to improve patient compliance and therapeutic outcomes, especially in the management of chronic diseases. In addition, long-acting MNs could avoid gastrointestinal reactions and reduce side effects, which has potential value for clinical application. In this paper, advances in design strategies and applications of long-acting polymeric MNs are reviewed. We also discuss the challenges in scale manufacture and regulations of polymeric MN systems. These two aspects will accelerate the effective clinical translation of MN products.

引用

页数：16